However, if future research shows that APOE alters other AD related proteinopathies in these patients, such as tau or α-synuclein or inflammation either directly or through altering Aβ levels, then certain APOE directed therapies may have more profound multi-target effects in an APOE isoform-dependent manner. Here, MAPT is linked to Alzheimer disease.